3Pineus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability,and increased mortality in seventy-flve rheumatoid arthritis patients studied over nine years [ J ]. Arthritis Rheum, 1984,27(8) :864-872.
4Arnett FC, Edworthy SM, Bloch DA, et al. The American rheuma- tism association 1987revised criteria for the classification of rheu- matoid arthritis [ J ]. Arthritis Rheum, 1988,31 (3) : 315-324.
5Prevoo ML,van't Hof MA,Kuper HH,et al. Modified disease ac- tivity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis [ J ]. Arthritis Rheum, 1995,38 ( 1 ) :44-48.
6BatlIon JM, Martin RW, Fleisehmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid ar- thritis[J]. N Eng| J Meal,2000,343(22) :1586-1593.
7Strand V, Cohen S, Schiff M, et al. Treatment of active rheumstoid arthritis with leflunomide compared with Placebo and methotrex- ate. Leflunomide Rheumatoid Arthritis Investigators Group [ J ]. Arch Intern Med, 1999,159 (21) :2542-2550.
8Wessels JA, de Vries-Bouwstra JK, Heijmans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis areasso- ciated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes [ J ]. Arthritis Rheum,2006,54 (4) : 1087- 1095.
